Status:
COMPLETED
Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder
Lead Sponsor:
AstraZeneca
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
66+ years
Phase:
PHASE3
Brief Summary
The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve depressive symptoms in eld...
Eligibility Criteria
Inclusion
- Male or female patients, 66 years or older, with a documented clinical diagnosis of MDD.
Exclusion
- The presence of dementia or mental disorder other than MDD within 6 months of enrolment,
- Uncontrolled hypertension, substance or alcohol abuse
- A current diagnosis of cancer or a current or past diagnosis of stroke
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
338 Patients enrolled
Trial Details
Trial ID
NCT00388973
Start Date
September 1 2006
End Date
December 1 2007
Last Update
April 1 2010
Active Locations (43)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Birmingham, Alabama, United States
2
Research Site
San Diego, California, United States
3
Research Site
Fort Myers, Florida, United States
4
Research Site
Gainsville, Florida, United States